سعر رايتيفلوكس 400 مجم أقراص 2025

Moxifloxacin 400 mg film-coated tablets (fluoroquinolone antibacterial), pack of 5, manufactured by Marcyrl for Pharma Right Group, Egypt.

• Community acquired pneumonia caused by designated susceptible bacteriaPopulation: Adults 18 years and olderDailyMed (U.S. National Library of Medicine)
• Uncomplicated skin and skin structure infections caused by designated susceptible bacteriaPopulation: Adults 18 years and olderDailyMed (U.S. National Library of Medicine)
• Complicated skin and skin structure infections caused by designated susceptible bacteriaPopulation: Adults 18 years and olderDailyMed (U.S. National Library of Medicine)

• Most common adverse reactions leading to discontinuation of 400 mg oral dosing: nausea, diarrhoea, dizziness and vomiting.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• History of hypersensitivity to moxifloxacin or any quinolone.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning: fluoroquinolones are associated with disabling and potentially irreversible serious reactions (tendinitis/tendon rupture, peripheral neuropathy, CNS effects) and may exacerbate myasthenia gravis; discontinue immediately if these occur.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• QT prolongation: avoid in patients with known QT prolongation, uncorrected hypokalaemia and with class IA or III antiarrhythmics.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Serious hypersensitivity/anaphylaxis and other serious, sometimes fatal reactions (severe skin reactions, hepatitis, nephritis, haematological effects) reported.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Multivalent cation products (antacids, sucralfate, multivitamins, iron, zinc)Decreased moxifloxacin absorption; take moxifloxacin 4 hours before or 8 hours after.DailyMed (U.S. National Library of Medicine)
• WarfarinEnhanced anticoagulant effect; monitor INR and bleeding.DailyMed (U.S. National Library of Medicine)
• Class IA and class III antiarrhythmicsProarrhythmic effect may be enhanced; avoid concomitant use.DailyMed (U.S. National Library of Medicine)

• No human data establish a drug-associated risk; based on animal studies, moxifloxacin may cause fetal harm (not teratogenic at clinical exposures; maternal-toxic doses caused fetal/neonatal effects).International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Unknown whether present in human milk; may be excreted based on rat data. Weigh benefits of breastfeeding against maternal need and potential infant effects.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Moxifloxacin: Bactericidal; inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes needed for DNA replication, transcription, repair and recombination.